MAIA
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc. (MAIA) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B+ (3.8) | B (3.4) | C- (2.1) | C (2.2) | C+ (2.6) | C+ (2.8) |
| 2026-11-06 | B+ (3.7) | B (3.4) | C (2.2) | C (2.3) | C+ (2.7) | B- (2.9) |
| 2026-10-30 | A- (3.9) | B (3.4) | C (2.2) | C (2.5) | C+ (2.7) | B- (2.9) |
| 2026-10-23 | B+ (3.8) | B (3.4) | C (2.2) | C+ (2.6) | C+ (2.6) | B- (2.9) |
| 2026-10-16 | B+ (3.7) | B (3.4) | C (2.2) | C+ (2.6) | C+ (2.6) | B- (2.9) |